Almirall S A - 2023 02 21
Almirall S A - 2023 02 21
Almirall S A - 2023 02 21
Net income 2022 28,1 M Net income 2023 31,5 M EV / Sales 2022 2,04x
Net Debt 2022 154 M Net Debt 2023 119 M EV / Sales 2023 1,91x
P/E ratio 2022 44,6x P/E ratio 2023 50,2x Nbr of Employees 1 786
Dermatology in the United States 100.18 12.4% 92.49 11.2% -7.68% Managers
Europe and the Middle East 394.50 48.9% 406.90 49.2% +3.14% Senior Vice President-Industrial
Eloi Crespo Cervera
Operations
Spain 237.13 29.4% 250.17 30.2% +5.5%
America, Asia and Africa 149.59 18.5% 143.04 17.3% -4.38% Members of the board
Corporate Management and Revenue Not
26.20 3.2% 27.09 3.3% +3.37% Name Title
Allocated to Other Segments
Chairman & Chief Executive
EUR in Million Carlos Gallardo Piqué
Officer
Karin Louise Dorrepaal Independent Director
Equities
Seth J. Orlow Independent Director
Disclaimer : SURPERFORMANCE SAS assumes no responsibility for any use that may be made of the information available, and the consequences that may result, including any decision
taken on the basis of information provided, even in case of error or omission. The content is intended for investors who have the necessary knowledge and experience to understand and https://www.marketscreener.com
appreciate the information developed. These information are disseminated for information only. These information may contain inaccuracies, errors or omissions.
Page 1 / 6
PDF Report issued on the 17/02/2023
Capitalization 1 597 M € -
Enterprise Value (EV) 1 751 M € 1 716 M €
1 2 Estimates
EUR in Million EUR
EPS - Rate of surprise
Finances - Leverage : Past and Forecast
Disclaimer : SURPERFORMANCE SAS assumes no responsibility for any use that may be made of the information available, and the consequences that may result, including any decision
taken on the basis of information provided, even in case of error or omission. The content is intended for investors who have the necessary knowledge and experience to understand and https://www.marketscreener.com
appreciate the information developed. These information are disseminated for information only. These information may contain inaccuracies, errors or omissions.
Page 2 / 6
PDF Report issued on the 17/02/2023
Sell Buy
Number of Analysts 12
Consensus detail
Disclaimer : SURPERFORMANCE SAS assumes no responsibility for any use that may be made of the information available, and the consequences that may result, including any decision
taken on the basis of information provided, even in case of error or omission. The content is intended for investors who have the necessary knowledge and experience to understand and https://www.marketscreener.com
appreciate the information developed. These information are disseminated for information only. These information may contain inaccuracies, errors or omissions.
Page 3 / 6
PDF Report issued on the 17/02/2023
Chart Sector
Disclaimer : SURPERFORMANCE SAS assumes no responsibility for any use that may be made of the information available, and the consequences that may result, including any decision
taken on the basis of information provided, even in case of error or omission. The content is intended for investors who have the necessary knowledge and experience to understand and https://www.marketscreener.com
appreciate the information developed. These information are disseminated for information only. These information may contain inaccuracies, errors or omissions.
Page 4 / 6
PDF Report issued on the 17/02/2023
Basic data
Performance
1 day 0.03%
5 days -4.81%
1 week -3.59%
1 month -5.62%
3 months -0.17%
6 months -10.33%
1 year -18.00%
3 years -34.40%
5 years -2.57%
10 years -9.49%
Weekly chart
Disclaimer : SURPERFORMANCE SAS assumes no responsibility for any use that may be made of the information available, and the consequences that may result, including any decision
taken on the basis of information provided, even in case of error or omission. The content is intended for investors who have the necessary knowledge and experience to understand and https://www.marketscreener.com
appreciate the information developed. These information are disseminated for information only. These information may contain inaccuracies, errors or omissions.
Page 5 / 6
PDF Report issued on the 17/02/2023
Summary Ratings
• Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Investment
• From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Trading
Strengths
ESG Refinitiv B
• The difference between current prices and the average target price is rather important and implies a significant appreciation
potential for the stock.
Financials
Sales Growth
Weaknesses
Earnings Growth
• The company does not generate enough profits, which is an alarming weak point.
EBITDA / Sales
• The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.59 times its estimated
earnings per share for the ongoing year. Profitability
• For the past year, analysts have significantly revised downwards their profit estimates. Finances
• For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Valuation
• Over the past four months, analysts' average price target has been revised downwards significantly.
P/E ratio
• The overall consensus opinion of analysts has deteriorated sharply over the past four months.
EV / Sales
• Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the
company's future activity. Price to Book
• Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations. Price to Free Cash Flow
Yield
Momentum
Turnover review 12m
Turnover review 4m
Turnover review 7 days
Earnings revision 12m
Earnings revision 4m
Consensus
Analyst Opinion
Potential Price Target
Price target revision 4m
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Social
Social commitment
Human Rights
Product liability
Human Resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversies
Disclaimer : SURPERFORMANCE SAS assumes no responsibility for any use that may be made of the information available, and the consequences that may result, including any decision
taken on the basis of information provided, even in case of error or omission. The content is intended for investors who have the necessary knowledge and experience to understand and https://www.marketscreener.com
appreciate the information developed. These information are disseminated for information only. These information may contain inaccuracies, errors or omissions.
Page 6 / 6